Poolbeg Pharma wins Canadian patent for cancer drug POLB 001 to prevent dangerous immune reactions

Poolbeg Pharma has secured a Canadian patent for its drug candidate POLB 001, which aims to prevent cytokine release syndrome (CRS), a severe immune reaction caused by some cancer immunotherapies. This patent follows a similar approval in Australia and covers the use of p38 MAPK inhibitors like POLB 001 for CRS prevention. The patent strengthens the drug's appeal to partners ahead of interim trial data expected this summer from the TOPICAL study on multiple myeloma patients. Poolbeg's intellectual property now covers CRS and severe influenza treatments across multiple regions.